Multiple Myeloma Clinical Trial

Role of Osteocytes in Myeloma Bone Disease

Summary

Progress in the treatment of myeloma and myeloma bone disease has substantially increased overall survival, but relapse is inevitable and better treatment is needed. The bone microenvironment is tremendously complex, so that targeting single interactions between tumor and bone is unlikely to be effective. Treatments need to block centrally important, multifunctional pathways. The investigators data point to a central role of the osteocyte to induce heparanase, a multifunctional mediator of myeloma bone disease. Increased heparanase due to FGF23 may make systemic inhibitors of heparanase less effective in bone than elsewhere. FGF23 neutralizing antibodies have been developed for non-cancer conditions of FGF23 excess, such as chronic kidney disease (Shimada & Fukamoto, 2012), and could be used in MM alone or in combination with heparanase inhibitors. Complete neutralization of FGF23 has adverse effects, but neutralization of FGF23 excess may be practical, or in the future, suppression of excess FGF23 biosynthesis by osteocytes.

The investigators hope to determine serum FGF23 and heparanase, Dkk1 and plasma klotho levels in patients with newly diagnosed and relapsed myeloma compared to healthy controls with this exploratory study.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Age > 18 years but ≤ 95 years at the time of consent
Subjects must be English-speaking
Must voluntarily sign the most current informed consent and HIPAA documents prior to study participation.
Have no prior history of malignancy in the past 5 years with the exception of basal cell and squamous cell carcinoma of the skin. Other cancers with low potential for metastasis, such as in situ cancers can also be enrolled as healthy volunteers.
Have no known liver or kidney disorders

Exclusion Criteria:

Pregnant females will be excluded from the study.
Subjects allergic to xylocaine will be excluded.
Subjects with an acute illness (Ex. upper respiratory infection, viral illness) in the past seven days will be excluded.
History of bleeding disorders.
Subjects deemed incompetent by treating physician
Institutionalized, mentally disabled subjects
Subjects who are prisoners

Study is for people with:

Multiple Myeloma

Estimated Enrollment:

67

Study ID:

NCT02212262

Recruitment Status:

Completed

Sponsor:

Attaya Suvannasankha

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Indiana University Simon Cancer Center
Indianapolis Indiana, 46202, United States
VA Roudebush Medical Center
Indianapolis Indiana, 46202, United States

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Estimated Enrollment:

67

Study ID:

NCT02212262

Recruitment Status:

Completed

Sponsor:


Attaya Suvannasankha

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.